TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00543777

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastogram
Description: Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 2-Point Dixon Magnetic Resonance Imaging
Description: Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
Study: NCT03205176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5153
Description: AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5153
Description: AZD5153 is to be taken as oral capsules once or twice per day each day in 21 day cycles. Dosing will continue until disease progression or other study discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib, 300 mg, will be taken BID as oral capsules.
Study: NCT01205971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dental Preventive Services
Description: Written oral health educational materials
Study: NCT01548066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo
Description: spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
Study: NCT01773187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Study: NCT02340533

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysteroscopic endo-myometrial biopsy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: two dimensional trans-vaginal ultrasonography
Study: NCT01581632

Intervention type: DEVICE
Group type: OTHER
Intervention: LipiScan/LipiScan IVUS
Description: Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
Study: NCT04680559

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Free observation of the psychotherapist's own feelings, thoughts, distractions, biases and behavior in general for 8 weeks. Observations of these variables are recorded during psychotherapy sessions with patients participating in the research.
Study: NCT02896556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resin infiltrate
Description: A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
Study: NCT01267188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-98854
Description: powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
Study: NCT01773187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Study: NCT04160663

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Carotid Ultrasound
Description: Uses sound waves to examine the blood flow through the carotid arteries and to determine the elastic properties or stiffness of the artery.
Study: NCT02956941

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BCC on Essential Nutrition and Hygiene Actions (ENHAs)
Description: The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
Study: NCT02777489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
Study: NCT01180296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral micronized progesterone
Description: oral micronized progesterone = 400 mg oral micronized progesterone nightly from 16 to 34 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Identical Placebo tablet
Description: Identical Placebo tablet = placebo taking nightly from 16 to 34 weeks
Study: NCT02925624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Study: NCT00559221

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: FLAG+IDA
Description: Fludarabine, cytarabine, G-CSF
Study: NCT05130749

Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.

Intervention type: OTHER
Intervention: Questionnaire
Description: The questionnaire's first section asked for demographic information such as gender, age, the name of the primary healthcare centre, and level of education. The second section comprised sources of knowledge on COVID-19; respondents replied on a scale of 1 least used (1), occasionally (2), more frequently (3), and most used (4). The third section had six items pertaining to nurses' infection prevention and control methods with reference to COVID-19, and respondents replied on a scale of yes (2), occasionally (1), and no (0). Permission to use the questionnaire has been requested from the author and is awaited.
Study: NCT02921490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/MR examination.
Description: All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
Study: NCT03948061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry juice
Description: FruitSmart® Cherry Concentrate: Dark Sweet Cherry Juice Concentrate produced from dark sweet cherries to retain the characteristic color and flavor of the whole fruit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
Study: NCT05138627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral cryotherapy
Description: Ice application protocol developed by the researcher by scanning the literature was prepared by taking the opinions of 5 faculty members who are experts in their fields. Also, the chamber of physics engineers and the chamber of chemical engineers' opinion was taken for the necessary corrections or improvements regarding the chemical/physical structure of the ice and the method applied. In the content of the protocol, materials, preparation before intraoral ice application (written and visual), steps of intraoral ice application (written and visual), termination of intraoral ice application, recording of intraoral ice application, and situations to be considered are explained in detail respectively.
Study: NCT02989883

Intervention type: OTHER
Group type: OTHER
Intervention: peroral endoscopic myotomy
Description: The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
Study: NCT01618006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study: NCT02449278

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Patients in both arms will be given prednisone chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Patients in both arms will be given prednisone chemotherapy
Study: NCT01618006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
Study: NCT03141632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Evaluation visit with assessment of fluid intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Evaluation visit with assessment of fluid intake
Study: NCT03858374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transferred by air-suspending mattress
Description: Put mattress in advance on the bed. When patients need to be transferred from bed to bed, fill the mattress with gas and keep it inflated, then pull the mattress .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transferred by slide board
Description: When patients need to be transferred from bed to bed, insert slide board under patient, then pull the slide board.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transferred by bedsheet
Description: When patients need to be transferred from bed to bed, just lift the bedsheet.
Study: NCT03323177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gender specific nutritional standardized formula
Description: Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up only
Description: Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
Study: NCT01344083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1210
Description: 2 drops T1210 once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride
Description: 2 drops once a day Olopatadine
Study: NCT02956187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fiber supplement
Description: 3.5 g plantago ovata per day will be administered for 4 weeks.
Study: NCT04247373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: According to previous patient's response, the investigators will allocate the concentration of ropivacaine of next patient during Co2 insufflation. And, for this allocation of concentration of ropivacaine the investigators use biased coin design up-and-down method.
Study: NCT03839069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minor salivary gland transplantation
Description: The investigators will harvest the autologous labial salivary gland tissue and transplant to the upper and lower conjunctival fornix of the lesion eye.
Study: NCT02333058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Treosulfan dose per day is to be calculated by using BSA:~One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.~Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.~Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2.
Study: NCT01840345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-l-cysteine
Description: 1200 mg BID x 4 weeks
Study: NCT02756117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Lysine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal (0.9%) Saline
Study: NCT04384055

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound will be performed on patients undergoing investigation for covid-19 based on a nasopharyngeal PCR.
Study: NCT06399237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot Orthoses
Description: Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot Orthoses
Description: Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foot Orthoses
Description: Three types of foot orthoses (FO), Prefabricated FO, Custom FO, Custom with a 5° varus FO
Study: NCT04190732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician phone call
Description: Often, patients will not have contact with a physician during the waiting period between embryo transfer and the pregnancy test. Participants in the intervention group will receive a phone call from one physician 3 to 4 days after fresh or frozen embryo transfer to check in. The physician will introduce themselves and state they are a part of the research team.
Study: NCT06449495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRVANA
Description: NIRVANA is a medical device using semi-immersive virtual reality for motor and cognitive neuro-rehabilitation.~NIRVANA creates a sensory room where the patient can have an immersive and stimulating experience by interacting directly with different realistic scenarios. The system creates different scenarios on the wall or floor, and the patient interacts with the stimuli provided. A motion-analysis device detects the patient's behavior and based on the projected environment provides highly stimulating and rehabilitative audiovisual feedback with full whole-body immersion. The system is preconfigured with a series of exercises, which can be customized based on different types of patients, intervening on the level of difficulty, speed of execution and sensitive area of the projection.
Study: NCT01060696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefenamic acid or Hyoscine or placebo
Description: Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
Study: NCT03948061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo beverage
Description: Cherry flavored placebo beverage prepared from commercially available cherry syrup with food coloring and thickener to match the color and viscosity of the cherry concentrate.
Study: NCT03859908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodine Povacrylex 7 MG/ML / Isopropyl Alcohol 0.74 ML/ML
Description: As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
Study: NCT02017470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gender-tailored women's heart health outpatient programme
Study: NCT02926066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2-hAADC
Description: Dosage form: Aqueous solution Dose(s): 2.37x10\^11 vg/case(High dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect~Dosage form: Aqueous solution Dose(s): 1.81x10\^11 vg/case(Standard dose) Dosing schedule: Intracerebral infusion, single dose Mechanism of action (if known): supplement a gene defect
Study: NCT01187056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training programme
Description: 2 x 2 hours of training (workshops)
Study: NCT03859908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate 20 MG/ML / Isopropyl Alcohol 0.7 ML/ML
Description: As preoperative antiseptic, applied once as suggested by Centers for Disease Control recommendations in surgical asepsis
Study: NCT01899573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCinch® Ventriculoplasty System
Description: Percutaneous intervention for the treatment of functional mitral regurgitation
Study: NCT01984840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Study: NCT01187056

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training programme
Description: 2 x 2 hours of training (workshops)
Study: NCT03670615

Intervention type: OTHER
Group type: OTHER
Intervention: tDCS
Description: All study participants randomized to tDCS will receive active tDCS.
Study: NCT04677738

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. breve
Description: Probiotic capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of B. breve B-3 in the morning before breakfast for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule. Participants will be instructed to take 2 capsules of placebo for 4 weeks during the run-in period. On day 1 participants will be instructed to take 2 capsules of placebo in the morning before breakfast for 12 weeks.
Study: NCT02507609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate neuromuscular blockade
Description: TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromuscular blockade
Description: PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
Study: NCT03572621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.~Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.~Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.~Session 3: Presentation of available treatments, start intracavernous injections.~Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.~Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Collection of data concerning their sexuality
Description: Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).

Intervention type: OTHER
Group type: OTHER
Intervention: Participation
Description: Participation in a therapeutic education day.
Study: NCT03670615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: All study participants randomized to tDCS will receive active tDCS.
Study: NCT04631848

Intervention type: DEVICE
Intervention: ULTRASCORE™ Focused Force PTA Balloon
Description: The device will be used for percutaneous transluminal angioplasty (PTA) to dilatate calcified stenoses in below the knee vessels
Study: NCT02965430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AL-SENSE
Description: A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
Study: NCT03027349

Intervention type: OTHER
Intervention: No intervention are provided

Intervention type: OTHER
Intervention: No intervention are provided
Study: NCT02578199

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing and nutrition
Description: Motivational Interviewing and Nutritional Counseling
Study: NCT00543387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5108
Description: MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
Study: NCT03670615

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Participants will exercise at TRI according to an individualized exercise prescription.